Navigation Links
Antibody-coated stents: Indication of disadvantages
Date:11/14/2012

, the TRIAS-HR study suggested that the opposite was the case. This called the mechanism of action of antibody-stents into doubt. It could also not be excluded that the disadvantage of antibody-stents found in the studies was due to the early discontinuation of clopidogrel. He added that antibody-stents were just another example of how not only the medical device, but also its manner of application, were decisive, and that if we wanted reliable information on benefit, we had to consider both the product and its application.

Benefit studies on medical devices are both feasible and necessary

Contrary to what the manufacturers of medical devices often assert, these benefit studies are feasible. According to Jrgen Windeler: "If you take the patient's safety seriously, you have to insist on these studies. Antibody-stents have been used for many years, but we don't know how many patients have received this intervention. It is only now that we learn that its harm outweighs its benefit."

Procedure of report production

The G-BA commissioned IQWiG to prepare the report in an accelerated process, known as a "rapid report". Unlike the normal procedure, no preliminary reports are published in this case. Although a draft version of the report is reviewed by external experts, no hearing at which all interested parties can comment takes place.

The first report (Version 1.0) was prepared in the middle of August 2012 and sent to the G-BA. Shortly afterwards, the Institute was sent additional and previously unpublished data on the decisive study TRIAS-HR, which had been requested by the Institute from the responsible research group in Amsterdam (data on the overall rate of myocardial infarctions and revascularization). The report was then revised and Version 1.1 sent to the G-BA at the start of September 2012.


'/>"/>

Contact: Anna-Sabine Ernst
presse@iqwig.de
0049-221-356-850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Abiraterone: Indication of considerable added benefit in certain patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 03, 2014 UWDress.com, an experienced ... has added a lot of fashionable bridesmaid dresses ... the company has launched a special offer to celebrate ... price, from 20 to 60 percent off. , ... to announce our new fashionable bridesmaid dresses for consumers ...
(Date:9/2/2014)... Recently, BambooIndustry.com, an excellent company in ... strand woven bamboo floors to celebrate the ... its appreciation to the frequent callers, BambooIndustry.com launched a ... addition to strand woven floors, BambooIndustry.com provides many kinds ... floors, click strand woven floors, click lock floors, wide ...
(Date:9/2/2014)... 03, 2014 Recently, Top 10 ... companies and announced that JustHost ( http://www.justhost.com/track/seohosts ) ... webmasters. , “The hosting suppliers we recommend are ... competitors on hosting features, uptime and server speed ... Best SEO Hosting says. “We believe that BlueHost ...
(Date:9/2/2014)... Cloud Medical Doctor Software Corporation (Cloud-MDs) (OTCQB: ... Business Operations solutions and Billing Services for the Healthcare ... for all industries announced today that its CEO Michael ... the CME in Chicago by PRICE Futures Group Mr. ... very proud of the recognition that our CipherLoc Encryption ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Complications are rare ... reconstruction, a new study indicates. However, the ... associated with a slightly higher risk for certain ... included more than 18,000 breast cancer patients who ... mastectomy with breast reconstruction and were followed for ...
Breaking Medicine News(10 mins):Health News:Elegant Bridesmaid Dresses For 2014, Latest Designs From UWDress.com 2Health News:Cheap Strand Woven Bamboo Floors For Autumn On Sale At BambooIndustry.com 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2
... diagnosis and treatment of breast cancer-related lymphedema by a ... for intensive rehabilitation, according to an article published in ... the scientific journal of the American Physical Therapy Association ... and spokesperson Nicole Stout, PT, MPT, CLT-LANA, compared a ...
... Air pollution may increase the risk of type 2 diabetes ... study suggests. Previous research has shown that air pollution ... and heart attack, but it hasn,t been known whether it ... and high blood pressure (hypertension). In this study, researchers ...
... 6 (HealthDay News) -- Two new studies from the Mayo ... to blame for a surge in liver cancer cases, which ... hepatocellular carcinoma (HCC), or liver cancer, has only a 10 ... in a Mayo news release. The researchers say their findings ...
... HealthDay Reporter , FRIDAY, Jan. 6 (HealthDay News) ... may have a different type of disease than those with ... well for them, new research suggests. "We are beginning ... molecular mechanisms," said Dr. John Fahy, director of the Airway ...
... new UCSF analysis of tobacco industry documents shows that ... additives in cigarettes, including menthol, obscuring actual toxicity levels ... diseases for smokers. Tobacco industry information can,t be ... their work provides evidence that hundreds of additives, including ...
... of the Journal of the American College of ... pediatric computed tomography (CT) scans. Approximately seven to eight ... indications per year in the United States. ... of reducing radiation dose with CT scanning. A substantial ...
Cached Medicine News:Health News:Prospective surveillance model emerges as standard of care for breast cancer treatment 2Health News:Smog Tied to Raised Risk of Chronic Illness in Black Women 2Health News:Researchers Identify Liver Cancer Risk Factors 2Health News:Study Offers Clues to Why Some Don't Benefit From Asthma Drugs 2Health News:Study Offers Clues to Why Some Don't Benefit From Asthma Drugs 3Health News:Tobacco company misrepresented danger from cigarettes 2Health News:Experts offer pointers for optimizing radiation dose in pediatric CT 2
(Date:9/2/2014)... , Spanje, September 2, 2014 ... GARFIELD AF Registry bij het ESC CONGRESS ... bij patiënten met risico op beroerte in ... Gegevens van bijna 12.500 patiënten ingeschreven ... FIELD-Atrial Fibrillation (GARFIELD-AF), een innovatief, onafhankelijk initiatief ...
(Date:9/2/2014)... , September 2, 2014 ... ESC CONGRESS 2014 provide insight into treatment and ... everyday clinical practice --   Data ... Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an ... stroke prevention strategies for atrial fibrillation (AF) patients ...
(Date:9/2/2014)... -- , Registry provides new insights into ... treatment satisfaction [ 1 ] , ...        (Photo: http://photos.prnewswire.com/prnh/20140902/703596 ) ... Barcelona, Spain : Daiichi Sankyo today announced ... Registry in Atrial Fibrillation (PREFER in AF), revealing significant ...
Breaking Medicine Technology:Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8
... 2011 Curemark, LLC , a drug research ... diseases, announced today that its compound CM-182 demonstrated positive ... amphetamines. The mouse model screening was performed by the ... indicated that the amphetamine-injected C57BL/6 mice exhibited a dose ...
... Valeant Pharmaceuticals International, Inc. (the "Company" or "Valeant") ... approved an increase of $300 million under its ... Program").  Under the Securities Repurchase Program, Valeant may ... convertible notes, senior notes, common shares and/or other ...
Cached Medicine Technology:Curemark Reports Positive Results for Novel Compound CM-182 in Amphetamine Induced Hyperactivity 2Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program 2Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program 3
Two prong stainless steel tips; with titanium handle/...
Straight shafts with fine Pierse type tips on a 5mm platform; In Titanium...
Smooth colibri tip; In Titanium....
Gently curved 5mm Platform With 12, 0.12mm Teeth; In Titanium....
Medicine Products: